THE USE AND OUTCOMES OF MEN WITH NCCN FAVORABLE INTERMEDIATE RISK PROSTATE CANCER MANAGED WITH ACTIVE SURVEILLANCE

被引：0
|
作者：
Paudel, Roshan
Madan, Raghav
Qi, Ji
Cher, Michael
Lane, Brian
George, Arvin
Semerjian, Alice
Ginsburg, Kevin
机构：
来源：
JOURNAL OF UROLOGY | 2022年 / 207卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP43-11
引用
收藏
页码：E745 / E745
页数：1
相关论文
共 50 条
  • [1] Oncological Outcomes in Men With Favorable Intermediate Risk Prostate Cancer Enrolled in Active Surveillance
    Pepe, Pietro
    Pepe, Ludovica
    Pennisi, Michele
    Fraggetta, Filippo
    [J]. IN VIVO, 2024, 38 (03): : 1300 - 1305
  • [2] Are men with favorable intermediate-risk prostate cancer candidates for active surveillance?
    Raldow, Ann Caroline
    Zhang, Danjie
    Chen, Ming-Hui
    Braccioforte, Michelle H.
    Moran, Brian Joseph
    D'Amico, Anthony Victor
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [3] Outcomes for Men with Intermediate-risk Prostate Cancer on Active Surveillance
    Courtney, P. T.
    Deka, R.
    Cherry, D. R.
    Nelson, T. J.
    Luterstein, E.
    Salans, M. A.
    Yip, A. T. T.
    Nalawade, V.
    Parsons, J. K.
    Kader, K.
    Stewart, T. F.
    Rose, B. S.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S121 - S122
  • [4] Outcomes of Active Surveillance for Men With Intermediate-Risk Prostate Cancer
    Cooperberg, Matthew R.
    Cowan, Janet E.
    Hilton, Joan F.
    Reese, Adam C.
    Zaid, Harras B.
    Porten, Sima P.
    Shinohara, Katsuto
    Meng, Maxwell V.
    Greene, Kirsten L.
    Carroll, Peter R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (02) : 228 - 234
  • [5] Prognostic Value of the Intermediate Risk Feature in Men with Favorable Intermediate Risk Prostate Cancer: Implications for Active Surveillance
    Sherer, M.
    Nelson, T. J.
    Courtney, P. T.
    Guram, K.
    De Moraes, G. Rodrigues
    Bagrodia, A.
    Rose, B. S.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E246 - E247
  • [6] No significant difference in intermediate key outcomes in men with low- and intermediate-risk prostate cancer managed by active surveillance
    Karolina Cyll
    Sven Löffeler
    Birgitte Carlsen
    Karin Skogstad
    May Lisbeth Plathan
    Martin Landquist
    Erik Skaaheim Haug
    [J]. Scientific Reports, 12
  • [7] Intermediate-Term Outcomes for Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance
    Nyame, Yaw A.
    Almassi, Nima
    Haywood, Samuel C.
    Greene, Daniel J.
    Ganesan, Vishnu
    Dai, Charles
    Zabell, Joseph
    Reichard, Chad
    Arora, Hans
    Zampini, Anna
    Crane, Alice
    Hettel, Daniel
    Elshafei, Ahmed
    Fareed, Khaled
    Stein, Robert J.
    Berglund, Ryan K.
    Gong, Michael
    Jones, J. Stephen
    Klein, Eric A.
    Stephenson, Andrew J.
    [J]. JOURNAL OF UROLOGY, 2017, 198 (03): : 591 - 598
  • [8] No significant difference in intermediate key outcomes in men with low- and intermediate-risk prostate cancer managed by active surveillance
    Cyll, Karolina
    Loffeler, Sven
    Carlsen, Birgitte
    Skogstad, Karin
    Plathan, May Lisbeth
    Landquist, Martin
    Haug, Erik Skaaheim
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [9] Active Surveillance for Men with Intermediate Risk Prostate Cancer
    Agrawal, Vishesh
    Ma, Xiaoyue
    Hu, Jim C.
    Barbieri, Christopher E.
    Nagar, Himanshu
    [J]. JOURNAL OF UROLOGY, 2021, 205 (01): : 115 - 121
  • [10] Risk Group and Death From Prostate Cancer Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer
    Raldow, Ann C.
    Zhang, Danjie
    Chen, Ming-Hui
    Braccioforte, Michelle H.
    Moran, Brian J.
    D'Amico, Anthony V.
    [J]. JAMA ONCOLOGY, 2015, 1 (03) : 334 - 340
12345